Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment <scp>(COMFORT)‐I</scp> study-Reference-Cited by-同舟云学术

Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)‐I study

Published:2022-06-24 Issue:6 Volume:198 Page:1065-1068
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kosiorek Heidi E.¹^ORCID,Scherber Robyn M.²,Geyer Holly L.³,Verstovsek Srdan⁴^ORCID,Langlais Blake T.¹,Mazza Gina L.¹,Gotlib Jason⁵,Gupta Vikas⁶^ORCID,Padrnos Leslie J.⁷^ORCID,Palmer Jeanne M.⁷,Fleischman Angela⁸,Mesa Ruben A.⁹^ORCID,Dueck Amylou C.¹

Affiliation:

1. Department of Quantitative Health Sciences, Mayo Clinic Scottsdale Arizona USA

2. Blueprint Medicines Cambridge Massachusetts USA

3. Department of Internal Medicine, Mayo Clinic Scottsdale Arizona USA

4. Department of Leukemia MD Anderson Cancer Center Houston Texas USA

5. Stanford University Medical Center Palo Alto California USA

6. MPN Program, Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada

7. Department of Hematology and Oncology, Mayo Clinic Phoenix Arizona USA

8. Department of Hematology and Oncology University of California Irvine Irvine California USA

9. Mays Cancer Center at UT Health San Antonio MD Anderson San Antonio Texas USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18329

Reference15 articles.

1. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review

2. Patient-Reported Outcomes as Independent Prognostic Factors for Survival in Oncology: Systematic Review and Meta-Analysis

3. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors

4. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

5. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasms;Leukemia & Lymphoma;2024-06-02

2. Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study;Annals of Hematology;2024-03-13

3. Ph-Negative Chronic Myeloproliferative Neoplasms;Comprehensive Hematology and Stem Cell Research;2024

4. Quality of life and affecting factors in myelofibrosis patients;2023-08-31

5. Myelofibrosis;Blood;2022-11-23